Openly accessible

CDKL3 promotes osteosarcoma progression by activating Akt/PKB

He, Aina, Ma, Lanjing, Huang, Yujing, Zhang, Haijiao, Duan, Wei, Li, Zexu, Fei, Teng, Yuan, Junqing, Wu, Hao, Liu, Liguo, Bai, Yueqing, Dai, Wentao, Wang, Yonggang, Li, Hongtao, Sun, Yong, Wang, Yaling, Wang, Chunyan, Yuan, Ting, Yang, Qingcheng, Tian, Songhai, Dong, Min, Sheng, Ren and Xiang, Dongxi 2020, CDKL3 promotes osteosarcoma progression by activating Akt/PKB, Life science alliance, vol. 3, no. 5, pp. 1-16, doi: 10.26508/lsa.202000648.

Attached Files
Name Description MIMEType Size Downloads

Title CDKL3 promotes osteosarcoma progression by activating Akt/PKB
Author(s) He, Aina
Ma, Lanjing
Huang, Yujing
Zhang, Haijiao
Duan, WeiORCID iD for Duan, Wei orcid.org/0000-0001-5782-9184
Li, Zexu
Fei, Teng
Yuan, Junqing
Wu, Hao
Liu, Liguo
Bai, Yueqing
Dai, Wentao
Wang, Yonggang
Li, Hongtao
Sun, Yong
Wang, Yaling
Wang, Chunyan
Yuan, Ting
Yang, Qingcheng
Tian, Songhai
Dong, Min
Sheng, Ren
Xiang, Dongxi
Journal name Life science alliance
Volume number 3
Issue number 5
Article ID e202000648
Start page 1
End page 16
Total pages 16
Publisher Life Science Alliance, LLC
Place of publication [Woodbury, N.Y.]
Publication date 2020-05
ISSN 2575-1077
2575-1077
Keyword(s) Science & Technology
Life Sciences & Biomedicine
Biology
genetics
gene therapy
genetic disease
cell biology
cancer
Summary Osteosarcoma (OS) is a primary malignant bone neoplasm with high frequencies of tumor metastasis and recurrence. Although the Akt/PKB signaling pathway is known to play key roles in tumorigenesis, the roles of cyclin-dependent kinase–like 3 (CDKL3) in OS progression remain largely elusive. We have demonstrated the high expression levels of CDKL3 in OS human specimens and comprehensively investigated the role of CDKL3 in promoting OS progression both in vitro and in vivo. We found that CDKL3 regulates Akt activation and its downstream effects, including cell growth and autophagy. The up-regulation of CDKL3 in OS specimens appeared to be associated with Akt activation and shorter overall patient survival (P = 0.003). Our findings identify CDKL3 as a critical regulator that stimulates OS progression by enhancing Akt activation. CDKL3 represents both a biomarker for OS prognosis, and a potential therapeutic target in precision medicine by targeting CDKL3 to treat Akt hyper-activated OS.
Language eng
DOI 10.26508/lsa.202000648
Indigenous content off
HERDC Research category C1 Refereed article in a scholarly journal
Free to Read? Yes
Persistent URL http://hdl.handle.net/10536/DRO/DU:30136042

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in TR Web of Science
Scopus Citation Count Cited 2 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 16 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Wed, 08 Apr 2020, 15:09:58 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.